Goldman Sachs Group Inc Cytom X Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 12,000 shares of CTMX stock, worth $12,000. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,000
Previous 109,302 89.02%
Holding current value
$12,000
Previous $133,000 89.47%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$1.12 - $1.51 $108,978 - $146,926
-97,302 Reduced 89.02%
12,000 $14,000
Q2 2024

Aug 13, 2024
SELL
$1.21 - $5.13 $223,356 - $946,956
-184,592 Reduced 62.81%
109,302 $133,000
Q1 2024

May 15, 2024
BUY
$1.41 - $2.74 $414,390 - $805,269
293,894 New
293,894 $640,000
Q2 2023

May 14, 2024
SELL
$1.41 - $1.92 $4,483 - $6,105
-3,180 Reduced 23.74%
10,217 $17,000
Q2 2023

Aug 14, 2023
SELL
$1.41 - $1.92 $4,483 - $6,105
-3,180 Reduced 23.74%
10,217 $17,000
Q1 2023

May 14, 2024
SELL
$1.48 - $2.88 $133,979 - $260,717
-90,527 Reduced 87.11%
13,397 $20,000
Q1 2023

May 11, 2023
SELL
$1.48 - $2.88 $133,979 - $260,717
-90,527 Reduced 87.11%
13,397 $20,000
Q4 2022

May 14, 2024
SELL
$1.19 - $1.91 $35,425 - $56,858
-29,769 Reduced 22.27%
103,924 $166,000
Q4 2022

Feb 13, 2023
SELL
$1.19 - $1.91 $35,425 - $56,858
-29,769 Reduced 22.27%
103,924 $166,000
Q3 2022

May 14, 2024
SELL
$1.23 - $1.97 $66,234 - $106,082
-53,849 Reduced 28.71%
133,693 $194,000
Q3 2022

Nov 10, 2022
SELL
$1.23 - $1.97 $66,234 - $106,082
-53,849 Reduced 28.71%
133,693 $0
Q2 2022

May 14, 2024
BUY
$1.53 - $2.89 $286,939 - $541,996
187,542 New
187,542 $343,000
Q2 2022

Aug 15, 2022
SELL
$1.53 - $2.89 $873,701 - $1.65 Million
-571,047 Reduced 75.28%
187,542 $343,000
Q1 2022

May 16, 2022
BUY
$2.67 - $4.68 $324,786 - $569,289
121,643 Added 19.1%
758,589 $2.03 Million
Q4 2021

Feb 14, 2022
SELL
$3.87 - $7.39 $1.83 Million - $3.49 Million
-472,119 Reduced 42.57%
636,946 $2.76 Million
Q3 2021

Nov 10, 2021
BUY
$4.32 - $6.43 $4.79 Million - $7.13 Million
1,109,065 New
1,109,065 $5.65 Million

Others Institutions Holding CTMX

# of Institutions
68
Shares Held
50.4M
Call Options Held
112K
Put Options Held
8.3K
View Full List

About CytomX Therapeutics, Inc.

CTMX Quotes by TradingView
  • Ticker CTMX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,950,200
  • Market Cap $66M
  • Description
  • CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...
More about CTMX
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email